Brexit
News
The FAMHP asked more than 12,000 francophone university students about the use of stimulant drugs. 5% of them said to use stimulant medicines for non-medical use, in order to study better.
The European Medicines Agency (EMA) and the competent medicine authorities of the European member states, including the FAMHP, have been notified that in a small number of diabetes medicines based on metformin outside of the European Union, a nitrosamine contamination (NDMA, N-nitrosodimethylamine) has been detected. Currently, analyses are being performed on the medicines within the European Union.
As of 1 January 2020, medicines with only one active ingredient can be sold for treating coughs and colds.
The FAMHP launches PharmaStatus, the new online application that collects information about the availability of medicines in Belgium and makes it public. Current information will help patients, doctors, pharmacists and the pharmaceutical industry to limit the impact of unavailable medicines.
As recommended by the Belgian Health Care Knowledge Centre (KCE), a new step in the fight against anti-microbial resistance has been taken: the 2019 edition of the Belgian Antibiotic Policy Coordination Committee (BAPCOC)’s antibiotics guide is available online on the Belgian Pharmacotherapy Information Centre (CBIP) website.
The fourth #MedSafetyWeek runs from November 25 to 29, 2019. Competent authorities from all over the worlds are participating in a social media campaign to draw attention to the importance of reporting side effects of medicines. This year, the campaign focuses on possible interactions when various medicines are used at the same time.
In 2019, operation Pangea took on a new form. This operation focused on information collection, analysis and communication. For this twelfth edition, that took place from June 2018 to June 2019, the FAMHP provided the necessary data. Pangea is coordinated by INTERPOL and is specifically designed to intercept illegal and counterfeit medicinal products and devices.http://www.medicaments-par-internet.be
How can health authorities such as the Federal Agency for Medicines and Health Products (FAMHP), in cooperation with the FPS Public Health, Safety of the Food Chain and Environment (SPF Public Health), the National Institute for Illness and Invalidity Insurance (RIZIV) and the Federal Knowledge Centre for Health Care (KCE) involve patients more (pro)actively and put them in a more central position throughout the complete development cycle of innovative medications?